ASD-005 / Asdera - LARVOL DELTA

BEYOND TARGETING AB AND TAU: NOVEL FORMULATIONS OF ALPHA-CYCLODEXTRINS FOR THE SAFE (NOT OTOTOXIC) AND CONVENIENT (ORAL) PREVENTION AND TREATMENT OF ALZHEIMER’S DISEASE. (CTAD 2022) - "Most AD drugs are cholinesterase inhibitor (donepezil), glutamate regulator (memantine), or directly targeting betaamyloid (aducanumab) or tau-protein...With the new results showing that: • the MoA of HPbCD is via PLs, not cholesterol, • the clathrates ASD-005/ IFM of aCDs and C10 are intestinally absorbed and safe, • αCDs have systemic effects in various cardiometabolic conditions and diseases involving ELA axis dysregulation, • the FDA has accepted HP-CDs as drugs with activity across the BBB, several barriers against a more convenient, safer, and potentially more effective prevention and DMT for ND diseases have been overcome. Studies of HPbCD have often assumed that it acted by “depleting cholesterol” (Simons M, 1998, PNAS 95: 6460), rather than other lipids, including phospholipids, even though this was not fullly supported by evidence. For instance, an official name of “ABCA1, a membrane cholesterol transporter” (Yao J, 2012, J Exp Med 209: 2501) is..."

Alzheimer's Disease • Breast Cancer • CNS Disorders • Dementia • Genetic Disorders • Immunology • Inflammation • Lysosomal Storage Diseases • Metabolic Disorders • Movement Disorders • Oncology • Otorhinolaryngology • Rare Diseases • Solid Tumor • ABCA1